NewAmsterdam Pharma’s (NAMS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of NewAmsterdam Pharma (NASDAQ:NAMS) in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $48.00 price objective on the stock.

NAMS has been the subject of several other reports. Piper Sandler reissued an “overweight” rating and issued a $37.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Needham & Company LLC reiterated a “buy” rating and issued a $36.00 price target on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. Finally, Scotiabank boosted their price objective on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, December 11th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, NewAmsterdam Pharma presently has an average rating of “Buy” and a consensus price target of $38.17.

NewAmsterdam Pharma Stock Performance

NAMS stock opened at $23.42 on Tuesday. The business has a 50 day moving average price of $23.67 and a two-hundred day moving average price of $19.77. NewAmsterdam Pharma has a twelve month low of $15.19 and a twelve month high of $27.29.

Insider Buying and Selling at NewAmsterdam Pharma

In related news, major shareholder Nap B.V. Forgrowth sold 33,273 shares of NewAmsterdam Pharma stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $25.08, for a total transaction of $834,486.84. Following the completion of the sale, the insider now owns 11,778,760 shares of the company’s stock, valued at approximately $295,411,300.80. The trade was a 0.28 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold a total of 446,730 shares of company stock worth $11,438,695 over the last ninety days. Insiders own 19.50% of the company’s stock.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several hedge funds have recently bought and sold shares of the stock. FMR LLC increased its stake in shares of NewAmsterdam Pharma by 35.6% during the third quarter. FMR LLC now owns 330,412 shares of the company’s stock worth $5,485,000 after purchasing an additional 86,712 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in NewAmsterdam Pharma by 1,231.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,283 shares of the company’s stock valued at $3,972,000 after buying an additional 221,305 shares in the last quarter. State Street Corp increased its position in NewAmsterdam Pharma by 168.7% during the 3rd quarter. State Street Corp now owns 37,915 shares of the company’s stock worth $629,000 after buying an additional 23,805 shares during the period. abrdn plc lifted its holdings in shares of NewAmsterdam Pharma by 69.8% during the third quarter. abrdn plc now owns 129,060 shares of the company’s stock worth $2,142,000 after buying an additional 53,060 shares in the last quarter. Finally, Millennium Management LLC boosted its position in shares of NewAmsterdam Pharma by 23.0% in the second quarter. Millennium Management LLC now owns 1,165,429 shares of the company’s stock valued at $22,388,000 after acquiring an additional 217,902 shares during the period. 89.89% of the stock is currently owned by institutional investors and hedge funds.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.